Monoclonal antibodies targeting allergic immune effectors, including omalizumab (IgE), dupilumab (IL-4 and IL-13), reslizumab, benralizumab, and mepolizumab (IL-5), have shown efficacy in treating the eczema and other allergic manifestations (67). Here, IL4 is linked to Eczematoid dermatitis.